Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors / Science Translational Medecine
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 9, 2026, 4:22 am / permalink 20364 / 6 stories in 2 days
White House autism briefing linked to swift shifts in prescribing patterns / Medical Express
medicalxpress - A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, a…
#healthcare #pharmaceuticals #publichealth #governmentpolicy #infanthealth #hospitaloperations
Monday, March 9, 2026, 12:22 am / permalink 20354 / 2 stories in 2 days
Eli Lilly's new program aims to boost employer coverage of GLP-1s / Endpoints
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
#obesity #healthcare #pharmaceuticals #drugpricing #elililly #weightloss #healthcarefinance
Saturday, March 7, 2026, 10:21 pm / permalink 20341 / 16 stories in 3 days
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Saturday, March 7, 2026, 9:22 am / permalink 20321 / 3 stories in 4 days
New FDA bonus pilot to address 'workforce challenges' / Endpoints
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
#healthcare #pharmaceuticals #governmentpolicy #biotech #drugdevelopment #fda #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20312 / 2 stories in 4 days
FDA lifts hold on Intellia trial / Beckers
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, March 7, 2026, 12:23 am / permalink 20309 / 2 stories in 4 days
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC / Healthcare Dive
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20308 / 3 stories in 4 days
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology / MedCity
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease
Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 4 days
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma / MedCity
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance
Saturday, March 7, 2026, 12:22 am / permalink 20306 / 4 stories in 4 days
Hospitals urge regulators to halt drugmakers’ expanded 340B data policies / Healthcare Dive
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #hospitaloperations #healthcarefinance
Friday, March 6, 2026, 12:23 pm / permalink 20277 / 4 stories in 4 days
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express
medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #drugdevelopment #behavioralhealth
Friday, March 6, 2026, 12:23 pm / permalink 20276 / 8 stories in 4 days
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy / LiveScience
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth
Thursday, March 5, 2026, 4:23 pm / permalink 20233 / 4 stories in 5 days
Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less / ESMO
esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium
#healthcare #pharmaceuticals #publichealth #oncology
Thursday, March 5, 2026, 3:23 am / permalink 20175 / 3 stories in 6 days
Novo Nordisk inks $2.1B oral obesity drug deal / Beckers
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance
Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 21 stories in 8 days
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO
esmo - Findings from the PYNNACLE study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, March 2, 2026, 2:22 am / permalink 19973 / 8 stories in 9 days
Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance
Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 9 days
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 11 days
Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days
Novartis to build $23B radioligand therapy site / Beckers
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 11 days
Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days